Multiple Myeloma

Multiple myeloma is the second most prevalent hematologic cancer after non-Hodgkin lymphoma. While great strides have been made to improve survival rates with this disease, and positive outcomes have been attained, multiple myeloma remains an incurable disease. The purpose of this course is to provide healthcare professionals in contact with multiple myeloma patients the information necessary to provide optimum care, treatment, and patient education. In addition, members of the public may use this course to enhance their personal knowledge of the subject matter presented.


Upon completion of this course, you should be able to:


1. Review the history of multiple myeloma.

2. Describe the pathophysiology and differentiation of multiple myeloma.

3. Discuss the etiology, epidemiology, and clinical presentation of multiple myeloma.

4. Review multiple myeloma-associated physiology, including normal plasma cell formation, the significance of immunoglobulins, and bone homeostasis.

5. Discuss the diagnostic workup associated with multiple myeloma.

6. Describe the staging of multiple myeloma with prognostic indicators.

7. Discuss the role of glucocorticoids and bisphosphonates in the treatment of patients with multiple myeloma, incorporating regimens for relapsed/refractory disease with recognition of anticipated side effects.

8. Outline the role and action of the immunomodulators in the treatment of multiple myeloma, including side effects and patient education.

9. Discuss stem cell transplantation as a treatment option for multiple myeloma.

10. Discuss disease-related complications and potential oncologic emergencies associated with multiple myeloma, including interventions and treatment.


This 10-hour continuing education course is available for download for professional development; if continuing education credit is desired, please see instructions included in eBook.